ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS) Files An 8-K Other EventsItem 8.01 Other Events.
On October 9, 2018, OncoSec Medical Incorporated (the “Company”) completed the first closing of 5,333,333 shares of its $0.0001 par value common stock (the “Common Stock”) from the Company’s previously announced registered direct offering. In connection with the offering, on August 31, 2018, the Company entered into a stock purchase agreement (“Purchase Agreement”) with Alpha Holdings, Inc. The Company received total proceeds, before expenses, of $8 million in cash from the offering. There were no underwriting or placement agent fees associated with the offering. The second closing of 4,666,667 shares of Common Stock is expected to occur on or before December 15, 2018.
The Company registered the sale of the shares with the Securities and Exchange Commission (the “SEC”) to a Registration Statement on Form S-3, as amended (File No. 333-213036) (the “Registration Statement”) filed on August 9, 2016, and declared effective by the SEC August 26, 2016, covering shares of the Company’s Common Stock. The Company is filing this current report on Form 8-K in order to cause certain information contained herein and in the exhibits hereto to be incorporated into the Registration Statement by reference.
The summary of the Purchase Agreement set forth above does not purport to be complete and is subject to and qualified in its entirety by reference to the text of such agreement.
Item 9.01 Financial Statements and Exhibits.
ONCOSEC MEDICAL Inc ExhibitEX-5.1 2 ex5-1.htm 90 Park Avenue New York,…To view the full exhibit click here
About ONCOSEC MEDICAL INCORPORATED (NASDAQ:ONCS)
OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.
